New fractionated dosing regimen for anticancer drug significantly improves outcomes for older leukemia patients
Using fractionated doses of the targeted anticancer drug gemtuzumab ozogamicin allows for safer delivery of the drug into patients aged 50-70 years with acute myeloid leukaemia (AML) and substantially improves their outcomes. ...
Apr 4, 2012
0
0